ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,142.15
-0.06%
Dow Jones
38,778.10
0.49%
Gold vs US Dollar
2,320.205
-0.01%
Brent Oil
83.69
-0.25%
Bitcoin
65,733.17
-1.13%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Mesoblast Limited (MESO) Share Price

MESO Mesoblast Limited

7.24
-0.04 (-0.55%)
18 Jun 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Mesoblast Limited NASDAQ:MESO NASDAQ Depository Receipt  Sponsored ADR Australia
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.04 -0.55 7.24 7.15 7.30 7.45 7.22 7.22 65,099 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 19.85M -81.89M -0.1006 -11.23 919.44M
 Type  Size  Price  Time  Units 
 9 10 7.24 23:33:36 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore MESO News
03/06/202401:23GLOBEMesoblast Corporate Presentation at Investor Conference
30/04/202402:05GLOBEAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
26/03/202413:25APSFDA Commentary Sends Biotech Soaring During Premarket Hours
26/03/202402:34GLOBEUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
13/03/202423:30GLOBEMesoblast Successfully Completes Placement and Accelerated Entitlement Offer
10/03/202423:54GLOBEUnited States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
28/02/202422:57GLOBEMesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Period
Draw mode
Data Downloads for MESO

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Mesoblast Limited Articles